ARCUTIS BIOTHERAPEUTICS, INC. Inventory, Finished Goods, Net of Reserves
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) had Inventory, Finished Goods, Net of Reserves of $14.17 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Inventory, Net, Items Net of Reserve Alternative › Inventory, Finished Goods and Work in Process, Net of Reserves
us-gaap:InventoryFinishedGoodsNetOfReserves · last filed 2026-08-05
- 2026-06-30: Inventory, Finished Goods, Net of Reserves $14.17M.
- 2026-03-31: Inventory, Finished Goods, Net of Reserves $14.68M.
- 2025-12-31: Inventory, Finished Goods, Net of Reserves $12.55M.
- 2025-09-30: Inventory, Finished Goods, Net of Reserves $11.58M.
| Period end | Inventory, Finished Goods, Net of Reserves |
|---|---|
| 2026-06-30 | $14.17M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $14.68M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $12.55M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $11.58M 10-Q · filed 2025-10-28 |
| 2025-06-30 | $7.87M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $8.27M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $9.64M 10-K · filed 2026-02-25 |
| 2024-09-30 | $8.14M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $5.82M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $2.74M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $2.70M 10-K · filed 2025-02-25 |
| 2023-09-30 | $2.35M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $1.93M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $1.91M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $1.46M 10-K · filed 2024-02-27 |
| 2022-09-30 | $698.00K 10-Q · filed 2022-11-08 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |